Individuals who exhibit a single CF-causing mutation in CFTR and/or sweat chloride 30–59 mEq/L will be approached about their interest in reviewing the consent form for the ‘main’ study (“iPSC derivation and in vivo ETI treatment for 4 weeks”; see following section). Here, CFTR is linked to cystic fibrosis.